Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Ulcerative Colitis (UC) · Crohn Disease (CD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University Medical Center Groningen, Groningen, Netherlands
Contact: Study coordinator (Wouter B Nagengast, MD, PharmD, PhD) · w.b.nagengast@umcg.nl · +31(0)503612620

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

IBD · Crohn Disease · Ulcerative Colitis (UC)

Abroad (travel likely)RecruitingPHASE2

Paris, France

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Inflammatory Bowel Disease (IBD) · Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)Recruiting

Calgary, Canada · Fredericton, Canada

IBD Biomarker Discovery and Validation Platform

Crohn Disease (CD) · Ulcerative Colitis (UC) · Inflammatory Bowel Diseases (IBD)

Abroad (travel likely)Recruiting

Guangzhou, China · Guangzhou, China

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)Recruiting

Bonheiden, Belgium